Immatics N.v. · NASDAQ:IMTX
Immatics — Corporate Update (November 2021)
35 slides from Immatics's corporate update, Nov 9, 2021
Slide 1: ACTengine IMA200 TCR-T Programs Interim Phase 1a Update
© Immatics. Not for further reproduction or distribution. ACTengine® IMA200 TCR - T Programs Interim Phase 1a Update Cedrik Britten, Chief Medical Officer Harpreet Singh, Chief Executive Officer November 09, 2021 Additional late - breaking oral presentation at SITC Annual Meeting on November 13 , 20
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their res
Slide 3: Agenda
Agenda • Introduction & Summary • IMA203 Phase 1a Interim Update • Comprehensive Strategy to Target PRAME • ACTengine® IMA 200 Programs Update • Summary • Q&A 3
Slide 4: Introduction & Summary
eo8 immiatics — =r We = a 4 i Introduction & Summary
Slide 5: Immatics' Proprietary PRAME Peptide-HLA/TCR Pair
Immatics’ Proprietary PRAME Peptide - HLA/TCR Pair Broadly Expressed Target on Multiple Solid Cancers Combined with Highly Specific TCR Uterine carcinoma SqNSCLC Melanoma Ovarian carcinoma HNSCC Uveal melanoma 2 Peptide Target PRAME: • HLA - A*02 - restricted peptide identified by XPRESIDENT® quant.
Slide 6: ACTengine IMA203 PRAME Phase 1a Dose Escalation Interim Update
ACTengine® IMA203 PRAME – Phase 1a Dose Escalation Interim Update Objective responses observed across multiple tumor types at dose levels below 1 billion T cells originally presumed to be subtherapeutic 1 DLT: dose - limiting toxicity, since March 17, 2021 (reported DLT at DL2); 2 CRS: cytokine rele
Slide 7: Comprehensive Strategy to Target PRAME
Comprehensive Strategy to Target PRAME Focused and broad approach targeting PRAME: Aiming to maximize clinical benefit through ACT programs and TCR Bispecifics • Complete IMA203 Ph1a Dose Escalation with doses above 1 bn cells (DL4) • D etermine Recommended Phase 2 Dose (RP2D) in 1Q2022 • Initiate I
Slide 8: IMA203 Phase 1a Interim Update
IMA203 Phase 1a Interim Update 8
Slide 9: ACTengine IMA203 Patient Flow
ACTengine® IMA203 – Patient Flow 9 HLA - A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase ACTengine ® Manufacturing by Immatics Infusion of ACTengine® T cell Product Lymphodepletion 30 mg/m 2 Flu darabine 1 and 500 mg/m 2 Cy c
Slide 10: ACTengine IMA203 Key Objectives & Trial Design
ACTengine® IMA203 – Key Objectives & Trial Design Trial Design & Recruitment Status 1 Enrichment cohorts EC1 & EC2: patients infused with intermediate doses enabling infusion of patients with medical need during do se escalation observation periods, or in case of lower production yields; * One patie
Slide 11: ACTengine IMA203 Patient Characteristics & Manufacturing
ACTengine® IMA203 – Patient Characteristics & Manufacturing Heavily Pre - Treated Patients Across Multiple Solid Cancers Were Infused Data cut - off – 05 - Oct - 2021 Efficacy Population (N=16) Median (range) Age [years] 53 (18 – 65) Prior lines of systemic therapies 4 (2 - 8) Years from diagnosis 4
Slide 12: ACTengine IMA203 Safety Profile
ACTengine® IMA203 – Safety Profile Manageable & Transient Treatment - emergent Adverse Event s – No ≥ Grade 3 CRS or ICANS Adverse event All grades ≥ Grade 3 No . % No . % Patients with any adverse event 19 100.0 19 100.0 Adverse Events of Special interest Cytokine release syndrome 1 7 8 9.5 0 0.0 I
Slide 13: ACTengine IMA203 Best Overall Response Assessment (RECIST 1.1)
ACTengine ® IMA203 – Best Overall Response Assessment (RECIST 1.1) Multiple Objective Responses in Various Solid Cancer Indications During Dose Escalation 203 - DL1 - 01 203 - DL1 - 02 203 - DL1 - 03 203 - EC1 - 01 203 - EC1 - 02 203 - EC1 - 03 203 - DL2 - 01 203 - DL2 - 02 203 - DL2 - 03 203 - DL2
Slide 14: ACTengine IMA203 Change in Target Lesions
ACTengine ® IMA203 – Change in Target Lesions Objective Responses across Multiple Tumor Types at Doses below 1 billion Transduced Cells 1 RECIST1.1 response at the timepoint of maximum change of target lesions (week 12): PD due to new lesions ( leptomeningeal disease) at week 12 2 Patients dosed wit
Slide 15: ACTengine IMA203 Response Over Time
Patient ID Indication Dose 203 - DL1 - 01 Head & Neck Cancer DL1 203 - DL1 - 02 Head & Neck Cancer DL1 203 - DL1 - 03 Ovarian Cancer DL1 203 - EC1 - 01 Melanoma EC1 203 - EC1 - 02 Melanoma EC1 203 - EC1 - 03 Uveal Melanoma EC1 203 - DL2 - 01 Synovial Sarcoma DL2 203 - DL2 - 02 Synovial Sarcoma DL2 2
Slide 16: ACTengine IMA203 Engraftment, Persistence & Tumor Infiltration
ACTengine® IMA203 – Engraftment, Persistence & Tumor Infiltration Clinical Responses Consistent with Biological Data T cell Engraftment & Persistence Tumor Infiltration post I nfusion 2 1 Mann - Whitney U test, p=0.065 ; 2 Post infusion biopsies at week 6 (except one patient with SD at week 3); 3 Ma
Slide 17: ACTengine IMA203 Case Study: Confirmed Partial Response
ACTengine ® IMA203 – Case Study Patient IMA203 - DL3 - 01 Confirmed Partial Response with Deepening Tumor Regression in Multiple Lesions BL D42 D84 Liver metastasis Lung metastasis s.c. metastasis Data cut - off – 05 - Oct - 2021 62 - year - old female patient Metastatic uveal melanoma with h igh tu
Slide 18: ACTengine IMA203 Case Study: Partial Response Consistent with Biological Data
ACTengine ® IMA203 – Case Study Patient IMA203 - DL3 - 01 Partial Response Consistent with Biological Data 0 10 20 30 0 10000 20000 30000 40000 50000 0 50 100 150 50 70 90 Patient IMA203-DL3-01 Day I L - 6 p g / m l L D H µ m o l / ( s * L ) S - 1 0 0 m g / l LDH IL6 S-100 T cell Engraftment, Persis
Slide 19: Comprehensive Strategy to Target PRAME
Comprehensive Strategy to Target PRAME 19
Slide 20: Comprehensive Strategy to Target PRAME
Targeted 2022 Comprehensive Strategy to Target PRAME Phase 1b Cohort A: IMA203 Monotherapy in Focus Indications Phase 1b Cohort B: IMA203/Checkpoint Inhibitor Combination Therapy Phase 1b Cohort C: IMA203CD8 2nd gen Monotherapy Phase 1a: IMA203 Monotherapy Dose Escalation in Basket Trial TCR - T Tra
Slide 21: ACTengine IMA203CD8 Second-generation TCR-T
ACTengine® IMA203CD8 – Second - generation TCR - T Building on First - Gen IMA203 Success to Further Improve Anti - Tumor Activity • Engagement of CD4 T cells by CD8 co - transduction reported to boost anti - tumor activity in TCR - T trials • Functional superiority of a CD8 αβ IMA203 construct (IMA
Slide 22: ACTengine IMA203CD8 Preclinical Assessment of Anti-Tumor Efficacy
ACTengine® IMA203CD8 – Preclinical Assessment of Anti - Tumor Efficacy Co - Transduction of CD8 αβ Enhances Anti - Tumor Activity in Vitro 18 36 56 74 94 114134 152 172192 0.0 0.5 1.0 1.5 2.0 IMA203CD8 TCR IMA203 TCR Non - Transduced Control S erial Killing Assay – CD8 & CD4 T cells Engagement of CD
Slide 23: TCER IMA402 Half-Life Extended Bispecific for PRAME
TCER® IMA402 – A Novel Half - Life Extended Bispecific for PRAME 23 pHLA targeting TCR x High - affinity TCR with broad therapeutic window through XPRESIDENT® - guided affinity maturation (>1000x) 2 x Targets HLA - A*02 - restricted PRAME peptide with unusually high t arget density 3 x Complete tumo
Slide 24: ACTengine IMA TCR-T Programs Update
ACTengine® IMA 200 TCR - T Programs Update 24
Slide 25: ACTengine Programs Key Features
IMA201 IMA202 IMA203 IMA204 Cancer Target Peptide HLA - A*02 - presented peptide derived from MAGEA4/8 MAGEA1 PRAME COL6A3 exon 6 shown to be naturally and specifically presented on native tumor tissues at d ifferentiated high peptide target density 1 100 - 1,000 copies/cell 50 - 900 copies/cell 100
Slide 26: ACTengine Programs Status and Next Milestones
IMA201 IMA202 IMA203 IMA204 MAGEA4/8 MAGEA1 PRAME COL6A3 exon 6 Status Dose escalation ongoing Enrollment at target dose level (DL3) ongoing Enrollment at target dose level (DL4) ongoing IND - enabling studies close to completion Recruitment DL2 commenced N=2 pts treated DL3 commenced N=10 pts treat
Slide 27: Selected Solid Cancer Indications with Significant Target Prevalence
IMA201 IMA202 IMA203 IMA204 MAGEA4/8 MAGEA1 PRAME COL6A3 exon 6 Selected solid cancer indications with significant target prevalence 1 Sarcoma Subtypes – up to 80% Squamous NSCLC – 50% HNSCC – 35% Bladder Carcinoma – 30% Esophageal Carcinoma – 25% Uterine Carcinosarcoma – 25% Ovarian Carcinoma – 20%
Slide 28: ACTengine IMA201 & IMA202 Patient Characteristics
ACTengine® IMA201 & IMA202 – Patient Characteristics Heavily Pre - Treated Patients Were Infused during Dose Escalation Data cut - off – 17 - Sep - 2021 Characteristics in Efficacy Population Median (range) Age [years] 60 (27 – 68) Prior lines of systemic therapies 5 (3 - 7) Years from diagnosis 4 (
Slide 29: ACTengine IMA201 & IMA202 Safety Profile
Data cut - off – 17 - Sep - 2021 ACTengine® IMA201 & IMA202 – Safety Profile Treatment - emergent Adverse Event s Are Manageable, Transient and Expected for Cell Therapies Adverse event All grades ≥ Grade 3 No . % No . % Patients with any adverse event 1 2 100.0 1 2 100.0 Adverse Events of Special i
Slide 30: ACTengine IMA201, IMA202, IMA203 Change in Target Lesions
ACTengine ® IMA201, IMA202, IMA203 – Change in Target Lesions Disease Control in 23 of 28 Patients Across 3 TCR - T Trials and Multiple Solid Cancers IMA201 & IMA202: Data cut - off – 17 - Sep - 2021 and IMA203: Data cut - off – 5 Oct - 2021 30 1 RECIST1.1 response at the timepoint of maximum change
Slide 31: Acknowledgements to Patients and Investigators
University Hospital Dresden University Hospital Bonn University Hospital Würzburg Columbia University University of Pittsburgh MD Anderson Cancer Center University Hospital Hamburg Dr. D . Araujo Dr. A . Tsimberidou Dr. G . Blumenschein Dr. A . Kaseb Dr. Van Morris Dr. C . Bokemeyer Dr. W. Alsdorf D
Slide 32: Summary
e08 immiatics a Oe eo | -< ea > re | - aie nr a Summary
Slide 33: Unlocking Immunotherapies for Solid Cancer Patients
Unlocking Immunotherapies for Solid Cancer Patients IMA203 - PRAME Objective responses observed across multiple tumor types 33 82% Disease Control Rate 0 Grade ≥3 CRS or ICANS 1 <1bn T cells infused in almost all patients PRAME STRATEGY Maximizing the therapeutic potential of targeting PRAME ORR 2 a
Slide 34: Updated Immatics Pipeline
Updated Immatics Pipeline 34 Modality Product Candidate Status Preclinical Phase 1a 1 Phase 1b 1 Phase 2/3 Next Milestone ACTengine® Autologous ACT IMA201 (MAGEA4/8) Proprietary Complete dose escalation 2022 IMA202 (MAGEA1) Proprietary Complete dose escalation 1Q2022 IMA203 (PRAME) Proprietary Compl
Slide 35: immiatics
8oe immiatics | DELIVERING THE POWER , OF 1 GRE 1) CANCER PATIENTS j 7 ‘www.immatics.com Lin | ¥| a